Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A new AI-powered analysis tool called PROVIZ is being tested in Norwegian hospitals to diagnose prostate cancer. The tool helps doctors determine which patients need a biopsy, reducing the number of unnecessary procedures.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
A meta-analysis of individual patients with oligometastatic prostate cancer shows that metastasis-directed radiation therapy (MDT) significantly improves patient outcomes, including delayed disease progression and better quality of life. The study included 574 men and found a median of 7.6 months before disease progression in the MDT a...
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
A review decodes the comprehensive role of GDF15 in prostate cancer metabolism, chemoresistance, and clinical applications, highlighting its involvement in cachexia, bone metastasis, and drug resistance. The study also explores the synergistic power of combining GDF15 with established markers for improved diagnosis and prognosis.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
A phase 2 clinical trial is comparing three strategies to protect heart health in prostate cancer patients undergoing hormone therapy. The study will assess the impact of intermittent fasting, GLP-1 medication, and nutritional counseling on cardiovascular and metabolic risks associated with androgen deprivation therapy.
Researchers summarize the role of metabolic reprogramming in driving prostate cancer progression, highlighting key regulators and inter-pathway crosstalk mechanisms. Novel targeted therapeutic strategies targeting glucose, glutamine, and lipid metabolism are proposed to overcome current treatment bottlenecks.
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
Researchers at VCU Massey Comprehensive Cancer Center and VCU Institute of Molecular Medicine are developing a novel therapy using engineered immune cells to target advanced prostate cancer. The therapy, which uses genetically modified natural killer cells producing the IL-24S 'Superkine', has shown promise in early-stage studies.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Researchers from University Hospitals Seidman Cancer Center found that the optimal duration of hormone therapy for prostate cancer treatment varies by disease risk. For high-risk patients, longer courses of ADT provide diminishing benefits while increasing the risk of non-prostate cancer death.
A new long-term prediction tool estimates the risk of dying from prostate cancer by combining PSA levels with factors like family history, race, age, and other health conditions. The tool showed higher accuracy in predicting prostate cancer death over decades compared to existing models.
A new study from Mayo Clinic introduces MedEduChat, an EHR-integrated AI agent providing accurate and patient-specific prostate cancer education. The tool delivers clear explanations based on each patient's health record, improving confidence and understanding of diagnosis and treatment options.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
A new study found that a widely used genomic test can accurately identify African American men with early prostate cancer at high risk of recurrence. The Decipher classifier linked to faster recurrence rates and supports more personalized treatment choices. Genomic testing may help better match patients with the right treatment intensi...
Daily scans taken during prostate cancer radiotherapy can identify changes linked to future rectal bleeding as early as one week into treatment. This allows doctors to adapt radiotherapy to limit side effects while maintaining cancer control.
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
Researchers identified a mechanism driving neuroendocrine prostate cancer and developed a dual-drug treatment that slowed tumor growth in lab tests. The findings highlight ERRγ as a promising new therapeutic target for patients with limited treatment options.
The new department will drive the next generation of discovery and patient-centered care through advanced imaging and therapy. Key collaborations include UCLA Health, David Geffen School of Medicine, and UCLA Health Jonsson Comprehensive Cancer Center.
A new study suggests that chronological age should be considered when creating treatment plans for men with metastatic hormone-sensitive prostate cancer. Older patients are more likely to experience comorbid conditions and die from causes other than prostate cancer.
The new clinical cancer research center will support lung and genitourinary cancers, serving as a central hub for seven VA medical centers. The grant aims to improve access to precision oncology trials and patient care for veterans diagnosed at later stages.
A new USC study identified five genes linked to aggressive prostate cancer in people of African descent, including ATM, BRCA2, CHEK2, HOXB13 and PALB2. The researchers developed a method combining genetic risk scores with family history and specific variant presence for personalized monitoring and treatment strategies.
Researchers from Arc Institute, UCSF, and Fred Hutchinson Cancer Center identified PTGES3 as a key regulator of the androgen receptor in prostate cancer. The study found that PTGES3 contributes to tumor growth and suggests it could be a promising new target for treating aggressive prostate cancers.
A recent survey conducted by Orlando Health found that over one-third of men (38%) would rather endure stressful situations than discuss their prostate health. The reluctance to address this common issue often leads to delayed diagnosis and treatment, affecting men's quality of life.
The European Randomized Study of Screening for Prostate Cancer found that PSA screening can substantially reduce deaths from prostate cancer, with a 13% relative reduction in prostate cancer mortality after 23 years. However, the study also highlights the issue of overdiagnosis associated with PSA screening.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
A study led by Olaf Merkel and colleagues identified thyroid hormone receptor TRβ as a key driver of prostate cancer growth, with blocking the receptor inhibiting tumour development. The findings offer new perspectives for treating castration-resistant prostate cancer and provide a potential target for new drugs.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A clinical trial showed a new drug combination reduced deaths in patients with recurrent prostate cancer after surgery or radiation therapy. The combination of hormone therapy and enzalutamide cut the risk of death by 40%, offering a meaningful treatment option for high-risk patients.
Researchers developed a high-speed whole-body SPECT method to track tumor evolution and personalize prostate cancer treatment. The new approach enabled faster monitoring, allowing for earlier adjustments to treatment plans and improved patient outcomes.
A major international study has identified two enzymes that play a crucial role in helping prostate cancer cells grow and survive. Blocking these enzymes can destabilize the androgen receptor, making tumours more vulnerable to existing therapies.
A UK study of 10 million men found that prostate specific antigen (PSA) testing may not effectively target those most likely to benefit from the test. Many patients are being retested more frequently than recommended, even without symptoms or previous low PSA values.
A new drug combination has shown promising results in delaying the progression of advanced prostate cancer in patients with specific genetic mutations. The trial, led by UCL researchers, found that combining niraparib with standard treatment delayed disease recurrence and improved survival rates for eligible patients.
Paul Boutros, a pioneer in using AI and machine learning to analyze cancer data, is appointed as the new director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys. The cancer center will leverage computational tools to personalize therapies for cancer patients.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
A study found that stereotactic body radiotherapy (SBRT) after prostate surgery is safe and effective in preventing cancer recurrence, with low side effects and manageable treatment. The results suggest SBRT may be a faster and simpler option for men at risk of recurrent prostate cancer.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
Dr. Amar Kishan has been recognized for his groundbreaking research on radiation treatments for genitourinary system cancers. He is the recipient of the 2025 Steven A. Leibel Memorial Award, presented by ASTRO and ABR Foundation.
The NRG-GU005 clinical study shows that SBRT significantly improves bowel health-related quality of life in patients with localized immediate risk prostate cancer. However, no significant improvement was seen for urinary HRQOL, and SBRT was not superior to IMRT in terms of distant-free survival.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
A new clinical trial found that adding a PSMA-targeting agent to stereotactic radiation therapy doubled progression-free survival in patients with limited metastatic prostate cancer. The study also showed that the treatment delayed hormone therapy by 24 months and improved local control.
A new PSMA-targeting radioligand therapy added to stereotactic body radiotherapy (SBRT) more than doubled progression-free survival in men with recurrent prostate cancer, delaying the start of hormone therapy by up to 24 months. The study found minimal side effects and identified biological markers that may predict treatment benefits.
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
Dr. Eggener brings extensive expertise in prostate and testicular cancer detection, diagnosis, and treatment to UCLA Health. He aims to improve prostate cancer detection and treatment through research.
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A new study found that Black men often view their primary-care providers as gatekeepers for prostate cancer screening, but are frequently dismissed from getting PSA tests. The study's lead author notes that PSA testing can catch the disease earlier and reduce mortality rates by up to 30% if done in the 40s rather than the 50s.
A recent study found that RAB26 is mainly expressed in luminal and basal/intermediate prostate cancer cells, correlating with advanced pathological stage and poor patient prognosis. RAB26 promotes proliferation, migration, and invasion of PCa cells while inhibiting apoptosis.
A new study published in JAMA finds biparametric magnetic resonance imaging (MRI) to be more efficient than multiparametric MRI for prostate cancer diagnosis. By adopting biparametric MRI, the global healthcare system could see a substantial increase in scanner throughput and cost reduction.
A quicker and cheaper two-part MRI scan is just as effective as the current 30-40 minute scan in detecting prostate cancer. The PRIME trial confirms that this streamlined approach can diagnose cancer at the same rate as a full three-part scan, cutting scan time to 15-20 minutes and reducing costs.
A new study from Memorial Sloan Kettering Cancer Center shows the Make-an-IMPACT program improves global access to genomic testing for pediatric cancer patients. The program helps develop an experimental antibody that shows promise against metastatic cancer. Researchers also shed light on the origins of ERG-driven prostate cancer and f...
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
A novel nomogram predicts survival probabilities for patients with both prostate cancer and secondary primary malignancies (SPMs). The study also reveals a significant causal relationship between prostate cancer and urothelial carcinoma, particularly bladder and upper tract cancers.
Researchers have developed a novel urine-based test to identify prostate cancer using biomarkers TTC3, H4C5, and EPCAM. The three-biomarker panel accurately detected prostate cancer 91% of the time and ruled out non-cancerous conditions 84% of the time in validation studies.
Hong Kong Metropolitan University (HKMU) has achieved its first-ever technology licensing agreement with a UK-based healthcare company. The know-how licensing agreement is for a non-invasive electrochemical screening technology that offers a promising method for early detection of prostate cancer through a simple urine test.